医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Qurient Announces Collaboration Agreement with MSD to Evaluate Selective Triple Inhibitor Q702 in Combination With KEYTRUDA® (pembrolizumab)

2021年11月23日 AM09:00
このエントリーをはてなブックマークに追加


 

SEONGNAM-SI, Korea

Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the company has entered into a clinical collaboration agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA,, for clinical study of Q702, a triple inhibitor of Axl/Mer/CSF1R) in combination with MSD’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).

Under this agreement, Qurient will conduct a phase 1b/2 study in the U.S. and Korea to evaluate safety and efficacy of Q702 and KEYTRUDA in combination for the treatment of selected advanced solid tumors, including esophageal, gastric, hepatocellular, and cervical cancers.

Kiyean Nam, Ph.D., CEO of Qurient, said, “We are pleased to collaborate with MSD to evaluate Q702 in combination with KEYTRUDA for the treatment of esophageal, gastric, hepatocellular, and cervical cancers, where limited immuno-oncology treatment options are currently available. We have previously shown the potential additive benefit of Q702 in combination with anti-PD-1 therapy in preclinical models, so this combination study is designed to evaluate clinical benefit of Q702 and KEYTRUDA for patients.”

Terms of the collaboration were not disclosed.

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About Q702

Q702 is an orally available novel Axl/Mer/CSF1R inhibitor and is designed to modulate innate immune components leading to T cell activation. Q702 was also shown to increase antigen presentation in the tumor cells demonstrating dual mode of action. A phase 1/2 clinical trial is currently underway in the U.S. (Clinical Trials.gov Identifier: NCT04648254) to evaluate safety and efficacy of Q702 as a monotherapy treatment for solid cancers.

About Qurient

Qurient, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics for oncology and inflammatory diseases from discovery to human proof-of-concept through a virtual R&D project management platform. Qurient’s pipeline includes multiple drug candidates in preclinical to phase 2 clinical development. For more info, please visit www.qurient.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006506/en/

CONTACT

Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
  • 知临集团用于治疗神经母细胞瘤的再利用药物 SACT-1 获得FDA孤儿药资格
  • シャーロット・ディーン教授がバイオ医薬品AI担当主任科学者としてエクセンシアに参加
  • Charlotte Deane教授加入Exscientia,担任生物制剂人工智能首席科学家
  • Elpiscience Announces First Patient Dosed in US Phase I Clinical Trial of Anti-CD39 Monoclonal Antibody ES002 for Treatment of Advanced Solid Tumors